Sort
30,917 grants matching “tumor microenvironment”
Advancing RAS pathway targeted therapy in NF1-MPNST: effects of SHP2 and CDK4/6 inhibitors on the tumor and the tumor immune microenvironment
$554,153Christine Anne Pratilas · Johns Hopkins University · R01 · FY2023 · CA
Mechanical Stress and Lung Tumor Progression
$554,133Jeffrey A. Weiss · University Of Utah · R01 · FY2024 · CA
DCE MRI Study for Breast Cancer.
$554,092Sungheon Gene Kim · New York University School Of Medicine · R01 · FY2015 · CA
DCE MRI Study for Breast Cancer.
$554,092Sungheon Gene Kim · New York University School Of Medicine · R01 · FY2016 · CA
Discrete Frequency Infrared Spectroscopic Imaging for Breast Histopathology
$554,075Rohit Bhargava · University Of Illinois At Urbana-Champaign · R01 · FY2023 · EB
A Novel Anti-HER2/neu IgE for Breast Cancer Therapy
$554,058Manuel L Penichet · University Of California Los Angeles · R01 · FY2017 · CA
Stromal Regulation of Basal Cell Carcinoma Formation
$554,038Anthony E Oro · Stanford University · R01 · FY2022 · AR
Project 2
$554,018Paolo Provenzano · University Of Minnesota · P01 · FY2021 · CA
Project 2
$554,018Paolo Provenzano · University Of Minnesota · P01 · FY2025 · CA
Improving anti-tumor T cell immunity by targeting LDH-A functions beyond the Warburg effect
$553,873Vassiliki A Boussiotis · Beth Israel Deaconess Medical Center · R01 · FY2019 · CA
Core A: Pathobiology Core
$553,798Massimo F Loda · Columbia University Health Sciences · P01 · FY2022 · CA
Delineating Functional Immunity via Image-Guided PET
$553,790Nerissa Therese Viola · Wayne State University · R37 · FY2024 · CA
(PQC2) Localization as a determinant of cancer dormancy
$553,740Charles P Lin · Massachusetts General Hospital · R01 · FY2017 · CA
Project 1: Blood Immunomethylomic Markers of Outcome in Glioblastoma Patients
$553,721John K. Wiencke · University Of California, San Francisco · P50 · FY2018 · CA
Data Processing, Analysis and Modeling Unit
$553,655Dana Pe'er · Sloan-Kettering Inst Can Research · U2C · FY2019 · CA
Metabolic Therapy of GBM guided by MRS of hyperpolarized 13C-pyruvate
$553,640Lawrence D Recht · Stanford University · R01 · FY2016 · CA
Engineered Vaccines for Neoantigen Targeted Cancer Immunotherapy
$553,633John Tanner Wilson · Vanderbilt University · R01 · FY2023 · CA
Overcoming hypoxic resistance to anti-cancer therapy
$553,580Nicholas C Denko · Ohio State University · R01 · FY2024 · CA
Lactate production by tumor associated macrophages promotes tumorigenesis
$553,562Lev Becker · University Of Chicago · R01 · FY2025 · CA
A translational study of a synthetic lethality interaction of CD105 and androgen receptor signaling axis for castration-resistant prostate cancer patients
$553,550Neil A Bhowmick · Cedars-Sinai Medical Center · R01 · FY2024 · CA
A deubiquitination module controls Treg adaptation to tumor microenvironment
$553,526Deyu Fang · Northwestern University At Chicago · R01 · FY2022 · CA
Targeting Kinesin Family Member 15 for the Treatment of Cancer
$553,464Andrew K Godwin · University Of Kansas Medical Center · R01 · FY2019 · CA
Metabolic barriers to T cell activation in clear cell renal cell carcinoma
$553,322Jeffrey C Rathmell · Vanderbilt University Medical Center · R01 · FY2023 · CA
Optimizing Novel Immunotherapy Combinations Targeting the Tumor Microenvironment in Canine Spontaneous Osteosarcoma
$553,260Steven W. Dow · Colorado State University · U01 · FY2020 · CA
Artificial, Humanized Stem Cell Niches
$553,236Biju Parekkadan · Rutgers, The State Univ Of N.J. · R01 · FY2020 · EB